中国前列腺癌患者TMPRSS2::ETS融合基因发生率的meta分析

Occurrence of the TMPRSS2::ETS fusion gene in Chinese patients with prostate cancer:a meta-analysis

目的:通过meta分析研究中国前列腺癌患者中TMPRSS2::ETS融合基因的发生率。方法:通过PubMed、Web of Science、Google Scholar、中国知识资源总库(CNKI)、万方医学在线数据库和维普数据库进行系统检索。用QUADAS-2评估偏倚风险,并用Stata 12.0和Review Manager 5.3进行meta分析,评估TMPRSS2::ETS融合基因在中国前列腺癌患者中的发生率。结果:共纳入16项研究,发现在中国前列腺癌患者中TMPRSS2::ERG融合基因是TMPRSS2::ETS融合基因家族最主要的类型,其发生率为16.7%,95%可信区间为(14.5%,18.8%)。就样本类型而言,穿刺活检样本的融合基因发生率为17.9%,95%可信区间为(15.8%,20.1%);当使用免疫组化检测技术时,融合基因发生率为16.6%,95%可信区间为(13.0%,20.2%)。结论:中国前列腺癌患者中,TMPRSS2::ERG融合基因为主要类型,但其发生率较低,因此不宜将TMPRSS2::ERG融合基因作为国内前列腺癌患者的诊断标志。

OBJECTIVE:To use meta-analysis for assessing the occurrence of TMPRSS2::ERG fusion gene in Chinese patients with prostate cancer.METHODS:A systematic search was conducted through PubMed,Web of Science,Google Scholar,China knowledge Resource Database(CNKI),Wanfang Medical online Database and VIP Database.The risk of bias was assessed using QUADAS-2 and a meta-analysis was performed using Stata12.0 and Review Manager 5.3 to evaluate the occurrence of TMPRSS2::ERG fusion gene in Chinese prostate cancer patients.RESULTS:A total of 16 articles were included.The incidence rate of TMPRSS2::ERG fusion gene in prostate cancer was 16.7%[95%CI(14.5%,18.8%)].Regarding the type of samples,biopsy specimens showed the incidence rate of fusion gene was 17.9%[95%CI(15.8%,20.1%)].When using immunohistochemistry(IHC)detection technology,the incidence rate of fusion gene was 16.6%[95%CI(13.0%,20.2%)].CONCLUSION:The occurrence of TMPRSS2::ERG fusion gene was low in Chinese prostate cancer patients,therefore,the TMPRSS2::ERG fusion gene cannot be used as a diagnostic marker for Chinese prostate cancer patients.